Research Study

An Open-Label, Extension Study of the Effects of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)
Principal Investigator 
Ging-Yuek Robin Hsiung

Overview

Body Locations and Systems 
Disorders and Conditions 
ClinicalTrials.gov# 
NCT02245568
Status 
Closed to Recruitment
Study Start/End 
Feb 4, 2016 to Mar 31, 2017
Locations 
UBC Hospital
Name/Title 
Eloise Nicklin, Study Coordinator
Phone 
604-822-0324
Email Address 
eloise.nicklin@vch.ca
Purpose of Study 

The purpose of this study is to provide subjects who have completed participation in a Phase 2 or Phase 3 trial with TRx0237 continued access to therapy and to evaluate the long-term safety of TRx0237.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.